Metformin Hydrochloride side effects: what 57,453 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Metformin Hydrochloride
Who reports
57,453 reports · 73% serious · 5,658 with death outcome · 55% female
Used for
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )
What it is
Metformin hydrochloride extended-release tablets, USP contain the biguanidine antihyperglycemic agent, metformin, in the form of monohydrochloride salt.
Boxed warning
LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,164 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Heart sounds | 40 | 250.5 167.0–375.8ROR 250.7 · calibrated p 3e-10 ✓ | 137.1 EB05 105.0 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=40 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Pulmonary vasculitis | 114 | 98.0 79.6–120.6ROR 98.2 · calibrated p 2e-7 ✓ | 75.9 EB05 64.9 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=114 · ♀ 0% (drug 55%) | no trial arm names this drug |
| Neurologic neglect syndrome | 113 | 90.1 73.3–110.7ROR 90.2 · calibrated p 3e-7 ✓ | 71.0 EB05 60.7 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=113 · ♀ 100% (drug 55%) | no trial arm names this drug |
| Prolonged expiration | 40 | 63.5 45.3–88.9ROR 63.5 · calibrated p 5e-6 ✓ | 52.6 EB05 40.3 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=40 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Total lung capacity abnormal | 55 | 60.1 45.1–80.0ROR 60.1 · calibrated p 6e-6 ✓ | 50.6 EB05 40.3 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Hypocholesterolaemia | 44 | 59.3 43.1–81.7ROR 59.4 · calibrated p 7e-6 ✓ | 49.9 EB05 38.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=44 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Human rhinovirus test positive | 53 | 59.0 44.1–78.9ROR 59.1 · calibrated p 7e-6 ✓ | 49.8 EB05 39.5 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=53 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Capillaritis | 38 | 58.7 41.6–82.8ROR 58.7 · calibrated p 9e-6 ✓ | 49.3 EB05 37.5 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=38 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Lactic acidosis | 4,538 | 58.7 56.9–60.5ROR 63.5 · calibrated p 3e-6 ✓ | 50.4 EB05 49.2 · IC025 +5.6 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 47.2 · serious PRR 40.4 · 93% clinician | no trial arm names this drug |
| Carotid artery thrombosis | 118 | 57.1 47.0–69.3ROR 57.2 · calibrated p 7e-6 ✓ | 48.9 EB05 41.9 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=118 · ♀ 100% (drug 55%) | no trial arm names this drug |
| Alveolar osteitis | 54 | 51.6 38.8–68.7ROR 51.6 · calibrated p 2e-5 ✓ | 44.5 EB05 35.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=53 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Urinary tract discomfort | 56 | 50.2 38.0–66.5ROR 50.3 · calibrated p 2e-5 ✓ | 43.5 EB05 34.7 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=56 · ♀ 100% (drug 55%) | no trial arm names this drug |
| Spirometry abnormal | 65 | 44.3 34.2–57.3ROR 44.3 · calibrated p 4e-5 ✓ | 39.0 EB05 31.7 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=65 · ♀ 0% (drug 55%) | no trial arm names this drug |
| Cerebral hypoperfusion | 49 | 42.5 31.6–57.2ROR 42.6 · calibrated p 5e-5 ✓ | 37.5 EB05 29.5 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=49 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Euglycaemic diabetic ketoacidosis | 396 | 39.3 35.4–43.5ROR 39.5 · calibrated p 6e-5 ✓ | 35.3 EB05 32.5 · IC025 +4.9 3/3 methods agree | Labeled (related wording) related wording | serious n=391 · 100% clinician | no trial arm names this drug |
| Adjustment disorder | 118 | 35.4 29.3–42.7ROR 35.4 · calibrated p 1e-4 ✓ | 32.1 EB05 27.5 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=115 · ♀ 100% (drug 55%) | no trial arm names this drug |
| Pneumonia haemophilus | 42 | 33.6 24.4–46.0ROR 33.6 · calibrated p 2e-4 ✓ | 30.3 EB05 23.4 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=42 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Mite allergy | 55 | 33.5 25.4–44.2ROR 33.6 · calibrated p 2e-4 ✓ | 30.4 EB05 24.2 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Respiratory syncytial virus test positive | 54 | 29.5 22.3–38.9ROR 29.5 · calibrated p 4e-4 ✓ | 27.1 EB05 21.5 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=54 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Diabetic metabolic decompensation | 102 | 28.3 23.1–34.6ROR 28.3 · calibrated p 4e-4 ✓ | 26.1 EB05 22.1 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious n=102 | no trial arm names this drug |
| Hypoglycaemic coma | 203 | 26.8 23.3–31.0ROR 26.9 · calibrated p 5e-4 ✓ | 25.0 EB05 22.2 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=203 | no trial arm names this drug |
| Mycotic allergy | 56 | 25.3 19.3–33.2ROR 25.3 · calibrated p 8e-4 ✓ | 23.5 EB05 18.8 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=56 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Neuritis | 102 | 25.2 20.7–30.9ROR 25.3 · calibrated p 7e-4 ✓ | 23.5 EB05 19.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=101 · ♀ 0% (drug 55%) | no trial arm names this drug |
| Hyperlactacidaemia | 173 | 25.0 21.4–29.1ROR 25.0 · calibrated p 7e-4 ✓ | 23.3 EB05 20.5 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=173 | no trial arm names this drug |
| Antineutrophil cytoplasmic antibody positive | 46 | 24.0 17.8–32.3ROR 24.0 · calibrated p 0.001 ✓ | 22.3 EB05 17.4 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | serious n=46 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Facet joint syndrome | 199 | 24.0 20.8–27.7ROR 24.0 · calibrated p 9e-4 ✓ | 22.4 EB05 19.9 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=199 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Continuous haemodiafiltration | 61 | 23.3 18.0–30.2ROR 23.3 · calibrated p 0.001 ✓ | 21.8 EB05 17.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=59 · 100% clinician | no trial arm names this drug |
| Animal scratch | 57 | 22.2 17.0–29.0ROR 22.2 · calibrated p 0.001 ✓ | 20.8 EB05 16.7 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=57 · ♀ 100% (drug 55%) | no trial arm names this drug |
| Dust allergy | 55 | 21.5 16.4–28.2ROR 21.5 · calibrated p 0.002 ✓ | 20.2 EB05 16.1 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 0% (drug 55%) · 100% clinician | no trial arm names this drug |
| Bronchopulmonary aspergillosis allergic | 52 | 21.4 16.2–28.3ROR 21.4 · calibrated p 0.002 ✓ | 20.1 EB05 15.9 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=52 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Ketosis | 50 | 18.1 13.6–24.1ROR 18.1 · calibrated p 0.004 ✓ | 17.1 EB05 13.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=46 · 100% clinician | no trial arm names this drug |
| Personality disorder | 127 | 18.0 15.1–21.5ROR 18.0 · calibrated p 0.003 ✓ | 17.1 EB05 14.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=127 · ♀ 100% (drug 55%) | no trial arm names this drug |
| Peripheral venous disease | 191 | 17.9 15.4–20.6ROR 17.9 · calibrated p 0.003 ✓ | 17.0 EB05 15.1 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=188 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Conjunctivitis allergic | 69 | 17.6 13.8–22.4ROR 17.6 · calibrated p 0.004 ✓ | 16.7 EB05 13.6 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=69 · ♀ 0% (drug 55%) | no trial arm names this drug |
| Metabolic acidosis | 1,420 | 16.7 15.8–17.6ROR 17.1 · calibrated p 0.004 ✓ | 16.0 EB05 15.3 · IC025 +3.9 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 15.8 · serious PRR 12.9 · 91% clinician | no trial arm names this drug |
| Onychomadesis | 179 | 16.0 13.8–18.6ROR 16.1 · calibrated p 0.005 ✓ | 15.3 EB05 13.5 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=177 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Onychomycosis | 186 | 15.8 13.6–18.3ROR 15.8 · calibrated p 0.006 ✓ | 15.1 EB05 13.4 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Eosinophilic granulomatosis with polyangiitis | 85 | 15.6 12.6–19.4ROR 15.6 · calibrated p 0.006 ✓ | 14.9 EB05 12.4 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=85 · ♀ 0% (drug 55%) | no trial arm names this drug |
| Distributive shock | 93 | 15.6 12.7–19.2ROR 15.6 · calibrated p 0.006 ✓ | 14.9 EB05 12.5 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=93 · 100% clinician | no trial arm names this drug |
| Respiratory symptom | 111 | 14.7 12.1–17.7ROR 14.7 · calibrated p 0.008 ✓ | 14.0 EB05 12.0 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | serious n=109 · ♀ 0% (drug 55%) | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Hypoglycaemia | 1,979 | 7.77.3–8.0 | signal |
| Kidney injury | 5,508 | 4.44.3–4.6 | signal |
| Hyperglycaemia / diabetes | 4,018 | 4.34.1–4.4 | signal |
| Pancreatitis | 656 | 3.02.8–3.2 | signal |
| Rhabdomyolysis / myopathy | 531 | 2.42.2–2.6 | signal |
| Hyponatraemia | 494 | 2.22.1–2.5 | signal |
| Suicidality | 1,395 | 2.12.0–2.2 | raised |
| Fall / fracture | 1,948 | 1.91.8–2.0 | raised |
| Interstitial lung disease | 489 | 1.91.7–2.0 | raised |
| Heart failure | 879 | 1.81.7–1.9 | raised |
| Liver injury | 1,458 | 1.81.7–1.9 | raised |
| Anaemia | 1,346 | 1.61.6–1.7 | raised |
| Arrhythmia / qt | 835 | 1.61.5–1.7 | raised |
| Depression | 1,186 | 1.51.5–1.6 | raised |
| Serious infection | 3,200 | 1.51.5–1.6 | raised |
| Stroke | 1,030 | 1.51.4–1.6 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Lactic acidosis | 4,538 | 58.7 56.9–60.5ROR 63.5 · calibrated p 3e-6 ✓ | 50.4 EB05 49.2 · IC025 +5.6 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 47.2 · serious PRR 40.4 · 93% clinician | no trial arm names this drug |
| Diarrhoea (diarrhea) | 4,424 | 2.5 2.4–2.5ROR 2.6 · calibrated p 0.780 | 2.5 EB05 2.4 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 2.2 | no trial arm names this drug |
| Nausea | 3,589 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.747 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.7 | no trial arm names this drug |
| Acute kidney injury (sudden kidney damage) | 3,237 | 7.7 7.5–8.0ROR 8.1 · calibrated p 0.064 | 7.6 EB05 7.4 · IC025 +2.9 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 6.8 · serious PRR 6.0 | no trial arm names this drug |
| Fatigue (tiredness) | 3,167 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.629 | 1.5 EB05 1.4 · IC025 +0.5 | Not in label — unassessed | age-adj. PRR 1.2 · serious PRR 1.4 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 2,816 | 0.8 0.7–0.8ROR 0.7 · calibrated p 0.156 | 0.8 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.8 · serious PRR 1.0 | no trial arm names this drug |
| Vomiting | 2,665 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.987 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 2.0 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 2,657 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.775 | 1.7 EB05 1.6 · IC025 +0.7 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.5 | no trial arm names this drug |
| Headache | 2,331 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.536 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.4 | no trial arm names this drug |
| Off label use (used outside approved label) | 2,241 | 0.9 0.9–1.0ROR 0.9 · calibrated p 0.254 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.0 | no trial arm names this drug |
| Dizziness | 2,164 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.689 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.6 | no trial arm names this drug |
| Asthenia (weakness) | 2,114 | 2.0 1.9–2.1ROR 2.0 · calibrated p 0.969 | 2.0 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 1.8 | no trial arm names this drug |
| Pain | 2,102 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.458 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled — boxed warning exact term | age-adj. PRR 1.3 · serious PRR 1.1 | no trial arm names this drug |
| Fall | 1,941 | 2.1 2.0–2.2ROR 2.1 · calibrated p 0.990 | 2.1 EB05 2.0 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 1.8 | no trial arm names this drug |
| Malaise (feeling unwell) | 1,835 | 1.5 1.4–1.6ROR 1.5 · calibrated p 0.645 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled — boxed warning exact term | age-adj. PRR 1.4 · serious PRR 1.6 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Heart sounds — n=40, PRR 250.5
- Pulmonary vasculitis — n=114, PRR 98.0
- Neurologic neglect syndrome — n=113, PRR 90.1
- Prolonged expiration — n=40, PRR 63.5
- Total lung capacity abnormal — n=55, PRR 60.1
- Hypocholesterolaemia — n=44, PRR 59.3
- Capillaritis — n=38, PRR 58.7
- Carotid artery thrombosis — n=118, PRR 57.1
- Alveolar osteitis — n=54, PRR 51.6
- Urinary tract discomfort — n=56, PRR 50.2
✓ A hand-written Bradford Hill causality assessment exists for this drug: Metformin ↔ Lactic acidosis.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Metformin Hydrochloride?
In FDA FAERS, the most frequently co-reported reaction terms for Metformin Hydrochloride are lactic acidosis, diarrhoea, nausea, acute kidney injury, fatigue, vomiting. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Metformin Hydrochloride have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Do FAERS signals prove that Metformin Hydrochloride causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 7e41818c-60e9-4bcf-9586-7bb8d33d5e89, effective 20260615; matched on
openfda.generic_name.exact:"METFORMIN") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,204 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
METFORMIN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.